Treatment of human immunodeficiency virus-associated lipodystrophy with dermafat graft transfer to the malar area

Berish Strauch, Thomas Baum, Noah Robbins

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Acquired immunodeficiency syndrome, a death sentence two decades ago, has been transformed into a chronic disease with a life expectancy of many years, due to the advent of highly active antiretroviral therapy. Despite virologic success, nearly 50 percent of patients on highly active antiretroviral therapy develop lipodystrophy with central and visceral fat accumulation and/or facial and limb fat atrophy. The changes are referred to as the human immunodeficiency virus lipodystrophy syndrome. The authors describe a series of five patients with antiretroviral therapy-induced lipodystrophy of the face who benefited from surgical correction of their typical stigmatizing malar atrophy. Dermafat grafts were transferred from the abdominal wall to malar pockets through a transoral approach. The aesthetic results were dramatic and stable, lasting the duration of the 1- to 2-year follow-up period.

Original languageEnglish (US)
Pages (from-to)363-370
Number of pages8
JournalPlastic and Reconstructive Surgery
Volume113
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

Lipodystrophy
Highly Active Antiretroviral Therapy
HIV
Transplants
Atrophy
Intra-Abdominal Fat
Abdominal Wall
Life Expectancy
Esthetics
Acquired Immunodeficiency Syndrome
Chronic Disease
Therapeutics
Extremities
Fats

ASJC Scopus subject areas

  • Surgery

Cite this

Treatment of human immunodeficiency virus-associated lipodystrophy with dermafat graft transfer to the malar area. / Strauch, Berish; Baum, Thomas; Robbins, Noah.

In: Plastic and Reconstructive Surgery, Vol. 113, No. 1, 01.2004, p. 363-370.

Research output: Contribution to journalArticle

@article{a4b49b53f4d9476b85819e9bd68beb5b,
title = "Treatment of human immunodeficiency virus-associated lipodystrophy with dermafat graft transfer to the malar area",
abstract = "Acquired immunodeficiency syndrome, a death sentence two decades ago, has been transformed into a chronic disease with a life expectancy of many years, due to the advent of highly active antiretroviral therapy. Despite virologic success, nearly 50 percent of patients on highly active antiretroviral therapy develop lipodystrophy with central and visceral fat accumulation and/or facial and limb fat atrophy. The changes are referred to as the human immunodeficiency virus lipodystrophy syndrome. The authors describe a series of five patients with antiretroviral therapy-induced lipodystrophy of the face who benefited from surgical correction of their typical stigmatizing malar atrophy. Dermafat grafts were transferred from the abdominal wall to malar pockets through a transoral approach. The aesthetic results were dramatic and stable, lasting the duration of the 1- to 2-year follow-up period.",
author = "Berish Strauch and Thomas Baum and Noah Robbins",
year = "2004",
month = "1",
doi = "10.1097/01.PRS.0000097288.27152.38",
language = "English (US)",
volume = "113",
pages = "363--370",
journal = "Plastic and Reconstructive Surgery",
issn = "0032-1052",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Treatment of human immunodeficiency virus-associated lipodystrophy with dermafat graft transfer to the malar area

AU - Strauch, Berish

AU - Baum, Thomas

AU - Robbins, Noah

PY - 2004/1

Y1 - 2004/1

N2 - Acquired immunodeficiency syndrome, a death sentence two decades ago, has been transformed into a chronic disease with a life expectancy of many years, due to the advent of highly active antiretroviral therapy. Despite virologic success, nearly 50 percent of patients on highly active antiretroviral therapy develop lipodystrophy with central and visceral fat accumulation and/or facial and limb fat atrophy. The changes are referred to as the human immunodeficiency virus lipodystrophy syndrome. The authors describe a series of five patients with antiretroviral therapy-induced lipodystrophy of the face who benefited from surgical correction of their typical stigmatizing malar atrophy. Dermafat grafts were transferred from the abdominal wall to malar pockets through a transoral approach. The aesthetic results were dramatic and stable, lasting the duration of the 1- to 2-year follow-up period.

AB - Acquired immunodeficiency syndrome, a death sentence two decades ago, has been transformed into a chronic disease with a life expectancy of many years, due to the advent of highly active antiretroviral therapy. Despite virologic success, nearly 50 percent of patients on highly active antiretroviral therapy develop lipodystrophy with central and visceral fat accumulation and/or facial and limb fat atrophy. The changes are referred to as the human immunodeficiency virus lipodystrophy syndrome. The authors describe a series of five patients with antiretroviral therapy-induced lipodystrophy of the face who benefited from surgical correction of their typical stigmatizing malar atrophy. Dermafat grafts were transferred from the abdominal wall to malar pockets through a transoral approach. The aesthetic results were dramatic and stable, lasting the duration of the 1- to 2-year follow-up period.

UR - http://www.scopus.com/inward/record.url?scp=4444246619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444246619&partnerID=8YFLogxK

U2 - 10.1097/01.PRS.0000097288.27152.38

DO - 10.1097/01.PRS.0000097288.27152.38

M3 - Article

C2 - 14707661

AN - SCOPUS:4444246619

VL - 113

SP - 363

EP - 370

JO - Plastic and Reconstructive Surgery

JF - Plastic and Reconstructive Surgery

SN - 0032-1052

IS - 1

ER -